Even though losartan is currently in widespread clinical use for the management of hypertension and stroke, miR-181b could potentially be a new or additive therapeutic target for intervention, targeting the TGF-β cascade independent of Angiotensin II. This evidence concerns the gene TGFB1 and stroke disorder.